Spinal Muscular Atrophy Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067472
  • December 2021
  • Pharmaceuticals
  • 154 Pages
Report Description

This report is a comprehensive study that examines the Spinal Muscular Atrophy Treatment industry in depth. With reference to key regions and major nations, the study specifies the product type of Spinal Muscular Atrophy Treatment as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Spinal Muscular Atrophy Treatment market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Spinal Muscular Atrophy Treatment market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Spinal Muscular Atrophy Treatment market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Spinal Muscular Atrophy Treatment Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Spinal Muscular Atrophy Treatment market study. The market dynamics and factors such as the threat of a Spinal Muscular Atrophy Treatment substitute, the threat of new entrants into the Spinal Muscular Atrophy Treatment market, buyer bargaining power, supplier bargaining power to Spinal Muscular Atrophy Treatment providing companies, and internal rivalry among Spinal Muscular Atrophy Treatment providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Spinal Muscular Atrophy Treatment market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Spinal Muscular Atrophy Treatment industry.
 
Spinal Muscular Atrophy Treatment Market Key Trends Analysis

The important factors influencing the growth of the Spinal Muscular Atrophy Treatment market have been examined in this report. The driving factors that are boosting demand for Spinal Muscular Atrophy Treatments and the restraining factors that are slowing growth of the Spinal Muscular Atrophy Treatment industry are addressed in depth, as well as their implications for the worldwide Spinal Muscular Atrophy Treatment market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Spinal Muscular Atrophy Treatment Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Spinal Muscular Atrophy Treatment industry. On the basis of current and future trends, all segments of the Spinal Muscular Atrophy Treatment industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Spinal Muscular Atrophy Treatment Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Spinal Muscular Atrophy Treatment market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Spinal Muscular Atrophy Treatment market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Spinal Muscular Atrophy Treatment market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Spinal Muscular Atrophy Treatment market. All important stakeholders in the Spinal Muscular Atrophy Treatment value chain and technological ecosystem are expected to benefit from the insights offered in the Spinal Muscular Atrophy Treatment market research study.

In order to provide a broader understanding of the top competitors in the Spinal Muscular Atrophy Treatment market, the research includes a company market share analysis. Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals, Chugai Pharmaceutical, Cure SMA, Cytokinetics, Inc., F. Hoffmann-La Roche AG, Genentech, Inc, Genzyme Corporation, Ionis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Natera, Inc, Novartis International AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Regeneron Pharmaceuticals, Inc., Salarius Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, UW Health are among the major participants in the global Spinal Muscular Atrophy Treatment industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals, Chugai Pharmaceutical, Cure SMA, Cytokinetics, Inc., F. Hoffmann-La Roche AG, Genentech, Inc, Genzyme Corporation, Ionis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Natera, Inc, Novartis International AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Regeneron Pharmaceuticals, Inc., Salarius Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, UW Health
 
Major Highlights of the Spinal Muscular Atrophy Treatment Market report study:
  • An in-depth examination of the global Spinal Muscular Atrophy Treatment industry will be published soon.
  • The study examines the global Spinal Muscular Atrophy Treatment market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Spinal Muscular Atrophy Treatment industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Spinal Muscular Atrophy Treatment market is being shaped by several major trends.
  • The size of the Spinal Muscular Atrophy Treatment market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Spinal Muscular Atrophy Treatment market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Spinal Muscular Atrophy Treatment market as follows:
Global Spinal Muscular Atrophy Treatment Market: By Product Type

  • Type I
  • Type II
  • Type III

Global Spinal Muscular Atrophy Treatment Market: By Application
  • Application I
  • Application II
  • Application III

Global Spinal Muscular Atrophy Treatment Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Spinal Muscular Atrophy Treatment market.
  • Universities and students
  • Other companies in the Spinal Muscular Atrophy Treatment market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Spinal Muscular Atrophy Treatment market

Manufacturers and Segments

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Catalyst Pharmaceuticals
  • Chugai Pharmaceutical
  • Cure SMA
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc
  • Genzyme Corporation
  • Ionis Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • Natera, Inc
  • Novartis International AG
  • Novo Nordisk A/S
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • PTC Therapeutics
  • Regeneron Pharmaceuticals, Inc.
  • Salarius Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • UW Health
  • Type I
  • Type II
  • Type III
  • Application I
  • Application II
  • Application III

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Spinal Muscular Atrophy Treatment Market Snapshot
          2.1.1. Global Spinal Muscular Atrophy Treatment Market By Type I,2019
               2.1.1.1.
               2.1.1.2.Type I I
               2.1.1.3.Type I II
          2.1.2. Global Spinal Muscular Atrophy Treatment Market By Application I,2019
               2.1.2.1.
               2.1.2.2.Application I I
               2.1.2.3.Application I II
          2.1.3. Global Spinal Muscular Atrophy Treatment Market By End-use,2019
          2.1.4. Global Spinal Muscular Atrophy Treatment Market By Geography,2019

3. Global Spinal Muscular Atrophy Treatment Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type I, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type I, 2020
     4.2. Global Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028

5. Global Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application I, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application I, 2020
     5.2. Global Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028

6. Global Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028

7. Global Spinal Muscular Atrophy Treatment Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Spinal Muscular Atrophy Treatment Market Analysis, 2018 – 2028 
          7.2.1. North America Spinal Muscular Atrophy Treatment Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028
          7.2.3. North America Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028
          7.2.4. North America Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Spinal Muscular Atrophy Treatment Market Analysis, 2018 – 2028 
          7.3.1.  Europe Spinal Muscular Atrophy Treatment Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028
          7.3.3. Europe Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028
          7.3.4. Europe Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Spinal Muscular Atrophy Treatment Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Spinal Muscular Atrophy Treatment Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028
          7.4.3. Asia Pacific Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028
          7.4.4. Asia Pacific Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Spinal Muscular Atrophy Treatment Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Spinal Muscular Atrophy Treatment Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028
          7.5.3. Latin America Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028
          7.5.4. Latin America Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Spinal Muscular Atrophy Treatment Market Analysis, 2018 – 2028 
          7.6.1.  MEA Spinal Muscular Atrophy Treatment Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Spinal Muscular Atrophy Treatment Market Size (US$), By Type I, 2018 – 2028
          7.6.3. MEA Spinal Muscular Atrophy Treatment Market Size (US$), By Application I, 2018 – 2028
          7.6.4. MEA Spinal Muscular Atrophy Treatment Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Spinal Muscular Atrophy Treatment Providers
        8.4.1 Astellas Pharma Inc.
                8.4.1.1 Business Description
                8.4.1.2 Astellas Pharma Inc. Geographic Operations
                8.4.1.3 Astellas Pharma Inc. Financial Information
                8.4.1.4 Astellas Pharma Inc. Product Positions/Portfolio
                8.4.1.5 Astellas Pharma Inc. Key Developments
        8.4.2 AstraZeneca PLC
                8.4.2.1 Business Description
                8.4.2.2 AstraZeneca PLC Geographic Operations
                8.4.2.3 AstraZeneca PLC Financial Information
                8.4.2.4 AstraZeneca PLC Product Positions/Portfolio
                8.4.2.5 AstraZeneca PLC Key Developments
        8.4.3 Biogen Inc.
                8.4.3.1 Business Description
                8.4.3.2 Biogen Inc. Geographic Operations
                8.4.3.3 Biogen Inc. Financial Information
                8.4.3.4 Biogen Inc. Product Positions/Portfolio
                8.4.3.5 Biogen Inc. Key Developments
        8.4.4 Boehringer Ingelheim GmbH
                8.4.4.1 Business Description
                8.4.4.2 Boehringer Ingelheim GmbH Geographic Operations
                8.4.4.3 Boehringer Ingelheim GmbH Financial Information
                8.4.4.4 Boehringer Ingelheim GmbH Product Positions/Portfolio
                8.4.4.5 Boehringer Ingelheim GmbH Key Developments
        8.4.5 Catalyst Pharmaceuticals
                8.4.5.1 Business Description
                8.4.5.2 Catalyst Pharmaceuticals Geographic Operations
                8.4.5.3 Catalyst Pharmaceuticals Financial Information
                8.4.5.4 Catalyst Pharmaceuticals Product Positions/Portfolio
                8.4.5.5 Catalyst Pharmaceuticals Key Developments
        8.4.6 Chugai Pharmaceutical
                8.4.6.1 Business Description
                8.4.6.2 Chugai Pharmaceutical Geographic Operations
                8.4.6.3 Chugai Pharmaceutical Financial Information
                8.4.6.4 Chugai Pharmaceutical Product Positions/Portfolio
                8.4.6.5 Chugai Pharmaceutical Key Developments
        8.4.7 Cure SMA
                8.4.7.1 Business Description
                8.4.7.2 Cure SMA Geographic Operations
                8.4.7.3 Cure SMA Financial Information
                8.4.7.4 Cure SMA Product Positions/Portfolio
                8.4.7.5 Cure SMA Key Developments
        8.4.8 Cytokinetics, Inc.
                8.4.8.1 Business Description
                8.4.8.2 Cytokinetics, Inc. Geographic Operations
                8.4.8.3 Cytokinetics, Inc. Financial Information
                8.4.8.4 Cytokinetics, Inc. Product Positions/Portfolio
                8.4.8.5 Cytokinetics, Inc. Key Developments
        8.4.9 F. Hoffmann-La Roche AG
                8.4.9.1 Business Description
                8.4.9.2 F. Hoffmann-La Roche AG Geographic Operations
                8.4.9.3 F. Hoffmann-La Roche AG Financial Information
                8.4.9.4 F. Hoffmann-La Roche AG Product Positions/Portfolio
                8.4.9.5 F. Hoffmann-La Roche AG Key Developments
        8.4.10 Genentech, Inc
                8.4.10.1 Business Description
                8.4.10.2 Genentech, Inc Geographic Operations
                8.4.10.3 Genentech, Inc Financial Information
                8.4.10.4 Genentech, Inc Product Positions/Portfolio
                8.4.10.5 Genentech, Inc Key Developments
        8.4.11 Genzyme Corporation
                8.4.11.1 Business Description
                8.4.11.2 Genzyme Corporation Geographic Operations
                8.4.11.3 Genzyme Corporation Financial Information
                8.4.11.4 Genzyme Corporation Product Positions/Portfolio
                8.4.11.5 Genzyme Corporation Key Developments
        8.4.12 Ionis Pharmaceuticals, Inc.
                8.4.12.1 Business Description
                8.4.12.2 Ionis Pharmaceuticals, Inc. Geographic Operations
                8.4.12.3 Ionis Pharmaceuticals, Inc. Financial Information
                8.4.12.4 Ionis Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.12.5 Ionis Pharmaceuticals, Inc. Key Developments
        8.4.13 Isis Pharmaceuticals, Inc.
                8.4.13.1 Business Description
                8.4.13.2 Isis Pharmaceuticals, Inc. Geographic Operations
                8.4.13.3 Isis Pharmaceuticals, Inc. Financial Information
                8.4.13.4 Isis Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.13.5 Isis Pharmaceuticals, Inc. Key Developments
        8.4.14 Natera, Inc
                8.4.14.1 Business Description
                8.4.14.2 Natera, Inc Geographic Operations
                8.4.14.3 Natera, Inc Financial Information
                8.4.14.4 Natera, Inc Product Positions/Portfolio
                8.4.14.5 Natera, Inc Key Developments
        8.4.15 Novartis International AG
                8.4.15.1 Business Description
                8.4.15.2 Novartis International AG Geographic Operations
                8.4.15.3 Novartis International AG Financial Information
                8.4.15.4 Novartis International AG Product Positions/Portfolio
                8.4.15.5 Novartis International AG Key Developments
        8.4.16 Novo Nordisk A/S
                8.4.16.1 Business Description
                8.4.16.2 Novo Nordisk A/S Geographic Operations
                8.4.16.3 Novo Nordisk A/S Financial Information
                8.4.16.4 Novo Nordisk A/S Product Positions/Portfolio
                8.4.16.5 Novo Nordisk A/S Key Developments
        8.4.17 PerkinElmer, Inc.
                8.4.17.1 Business Description
                8.4.17.2 PerkinElmer, Inc. Geographic Operations
                8.4.17.3 PerkinElmer, Inc. Financial Information
                8.4.17.4 PerkinElmer, Inc. Product Positions/Portfolio
                8.4.17.5 PerkinElmer, Inc. Key Developments
        8.4.18 Pfizer Inc.
                8.4.18.1 Business Description
                8.4.18.2 Pfizer Inc. Geographic Operations
                8.4.18.3 Pfizer Inc. Financial Information
                8.4.18.4 Pfizer Inc. Product Positions/Portfolio
                8.4.18.5 Pfizer Inc. Key Developments
        8.4.19 PTC Therapeutics
                8.4.19.1 Business Description
                8.4.19.2 PTC Therapeutics Geographic Operations
                8.4.19.3 PTC Therapeutics Financial Information
                8.4.19.4 PTC Therapeutics Product Positions/Portfolio
                8.4.19.5 PTC Therapeutics Key Developments
        8.4.20 Regeneron Pharmaceuticals, Inc.
                8.4.20.1 Business Description
                8.4.20.2 Regeneron Pharmaceuticals, Inc. Geographic Operations
                8.4.20.3 Regeneron Pharmaceuticals, Inc. Financial Information
                8.4.20.4 Regeneron Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.20.5 Regeneron Pharmaceuticals, Inc. Key Developments
        8.4.21 Salarius Pharmaceuticals, Inc.
                8.4.21.1 Business Description
                8.4.21.2 Salarius Pharmaceuticals, Inc. Geographic Operations
                8.4.21.3 Salarius Pharmaceuticals, Inc. Financial Information
                8.4.21.4 Salarius Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.21.5 Salarius Pharmaceuticals, Inc. Key Developments
        8.4.22 Takeda Pharmaceutical Company Limited
                8.4.22.1 Business Description
                8.4.22.2 Takeda Pharmaceutical Company Limited Geographic Operations
                8.4.22.3 Takeda Pharmaceutical Company Limited Financial Information
                8.4.22.4 Takeda Pharmaceutical Company Limited Product Positions/Portfolio
                8.4.22.5 Takeda Pharmaceutical Company Limited Key Developments
        8.4.23 UW Health
                8.4.23.1 Business Description
                8.4.23.2 UW Health Geographic Operations
                8.4.23.3 UW Health Financial Information
                8.4.23.4 UW Health Product Positions/Portfolio
                8.4.23.5 UW Health Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Spinal Muscular Atrophy Treatment Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Spinal Muscular Atrophy Treatment Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Spinal Muscular Atrophy Treatment Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Spinal Muscular Atrophy Treatment Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Spinal Muscular Atrophy Treatment Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Spinal Muscular Atrophy Treatment Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Spinal Muscular Atrophy Treatment Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Spinal Muscular Atrophy Treatment Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Spinal Muscular Atrophy Treatment Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Spinal Muscular Atrophy Treatment Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Spinal Muscular Atrophy Treatment Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Spinal Muscular Atrophy Treatment Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Spinal Muscular Atrophy Treatment Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Spinal Muscular Atrophy Treatment Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Spinal Muscular Atrophy Treatment Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Spinal Muscular Atrophy Treatment Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Spinal Muscular Atrophy Treatment: Market Segmentation 
FIG. 2 Global Spinal Muscular Atrophy Treatment Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Spinal Muscular Atrophy Treatment Market, By Type I, 2019 (US$ Mn) 
FIG. 5 Global Spinal Muscular Atrophy Treatment Market, By Application I, 2019 (US$ Mn) 
FIG. 6 Global Spinal Muscular Atrophy Treatment Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Spinal Muscular Atrophy Treatment Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Spinal Muscular Atrophy Treatment Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Spinal Muscular Atrophy Treatment Providers, 2019
FIG. 11 Global Spinal Muscular Atrophy Treatment Market Revenue Contribution, By Type I, 2019 & 2028 (Value %) 
FIG. 12 Global Spinal Muscular Atrophy Treatment Market Revenue Contribution, By Application I, 2019 & 2028 (Value %) 
FIG. 13 Global Spinal Muscular Atrophy Treatment Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Spinal Muscular Atrophy Treatment Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Spinal Muscular Atrophy Treatment Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Spinal Muscular Atrophy Treatment Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Spinal Muscular Atrophy Treatment Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Spinal Muscular Atrophy Treatment Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Spinal Muscular Atrophy Treatment market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Spinal Muscular Atrophy Treatment Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Spinal Muscular Atrophy Treatment Market Value, By Segment1, 2018 – 2028
TABLE  North America Spinal Muscular Atrophy Treatment Market Value, By Segment2, 2018 – 2028
TABLE  North America Spinal Muscular Atrophy Treatment Market Value, By Country, 2018 – 2028
TABLE  Europe Spinal Muscular Atrophy Treatment Market Value, By Segment1, 2018 – 2028
TABLE  Europe Spinal Muscular Atrophy Treatment Market Value, By Segment2, 2018 – 2028
TABLE  Europe Spinal Muscular Atrophy Treatment Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Spinal Muscular Atrophy Treatment Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Spinal Muscular Atrophy Treatment Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Spinal Muscular Atrophy Treatment Market Value, By Country, 2018 – 2028
TABLE  Latin America Spinal Muscular Atrophy Treatment Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Spinal Muscular Atrophy Treatment Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Spinal Muscular Atrophy Treatment Market Value, By Country, 2018 – 2028
TABLE  MEA Spinal Muscular Atrophy Treatment Market Value, By Segment1, 2018 – 2028
TABLE  MEA Spinal Muscular Atrophy Treatment Market Value, By Segment2, 2018 – 2028
TABLE  MEA Spinal Muscular Atrophy Treatment Market Value, By Country, 2018 – 2028
TABLE  Astellas Pharma Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca PLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biogen Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Boehringer Ingelheim GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Catalyst Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Chugai Pharmaceutical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cure SMA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cytokinetics, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Genentech, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Genzyme Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Ionis Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Isis Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Natera, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis International AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novo Nordisk A/S: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  PerkinElmer, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  PTC Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Regeneron Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Salarius Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Takeda Pharmaceutical Company Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  UW Health: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Spinal Muscular Atrophy Treatment Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Spinal Muscular Atrophy Treatment Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Spinal Muscular Atrophy Treatment Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Spinal Muscular Atrophy Treatment Market, By Geography, 2019 (US$ Mn)
FIG.  Global Spinal Muscular Atrophy Treatment Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Spinal Muscular Atrophy Treatment Providers, 2016
FIG.  Global Spinal Muscular Atrophy Treatment Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Spinal Muscular Atrophy Treatment Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Spinal Muscular Atrophy Treatment Market Value, 2018 – 2028, (US$ Mn)